If approved, the pill is expected to be far easier to administer than current injectables — and far easier to manufacture.

Positive data on the pill and a potential approval would be a boon to Eli Lilly, but could also be good news for other companies developing oral GLP-1s, according to some analysts. Orforglipron ...